Anika Therapeutics Statistics
Anika Therapeutics (AKP) Stock Statistics & Valuation Metrics
Total Valuation
Anika Therapeutics has a market cap or net worth of CHF 159.60M. The enterprise value is CHF 244.40M.
- Market Cap
- CHF 159.60M
- Enterprise Value
- CHF 244.40M
Share Statistics
Anika Therapeutics has 13,382,966 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,382,966
- Owned by Insiders
- 5.00%
- Owned by Institutions
- 29.81%
Financial Efficiency
Anika Therapeutics’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -6.48%.
- Return on Equity (ROE)
- -0.08
- Return on Assets (ROA)
- -0.06
- Return on Invested Capital (ROIC)
- -6.48%
- Return on Capital Employed (ROCE)
- -0.07
- Revenue Per Employee
- 480.08K
- Profits Per Employee
- -46.30K
- Employee Count
- 235
- Asset Turnover
- 0.59
- Inventory Turnover
- 2.61
Valuation Ratios
The current PE Ratio of Anika Therapeutics is -101.51. Anika Therapeutics’s PEG ratio is -0.33.
- PE Ratio
- -101.51
- PS Ratio
- 1.46
- PB Ratio
- 1.31
- Price to FCF
- 78.55
- Price to Operating Cash Flow
- 24.10
- PEG Ratio
- -0.33
Income Statement
In the last 12 months, Anika Therapeutics had revenue of 112.82M and earned -10.88M in profits. Earnings per share was -0.76.
- Revenue
- 112.82M
- Gross Profit
- 63.81M
- Operating Income
- -11.05M
- Pretax Income
- -9.31M
- Net Income
- -10.88M
- EBITDA
- -3.58M
- Earnings Per Share (EPS)
- -0.76
Cash Flow
In the last 12 months, operating cash flow was 7.48M and capital expenditures -5.19M, giving a free cash flow of 2.29M billion.
- Operating Cash Flow
- 7.48M
- Free Cash Flow
- 2.29M
- Free Cash Flow per Share
- 0.17
Dividends & Yields
Anika Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.23%
- Earnings Yield
- -0.95%
Stock Price Statistics
- Beta
- 0.98
- 52-Week Price Change
- ―
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Anika Therapeutics upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Anika Therapeutics as a current ratio of 4.72, with Debt / Equity ratio of 18.30%
- Current Ratio
- 4.72
- Quick Ratio
- 3.86
- Debt to Market Cap
- 0.18
- Net Debt to EBITDA
- 8.73
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Anika Therapeutics has paid 672.00K in taxes.
- Income Tax
- 672.00K
- Effective Tax Rate
- -0.07
Enterprise Valuation
Anika Therapeutics EV to EBITDA ratio is 58.28, with an EV/FCF ratio of 72.14.
- EV to Sales
- 1.34
- EV to EBITDA
- 58.28
- EV to Free Cash Flow
- 72.14
- EV to Operating Cash Flow
- 22.12
Balance Sheet
Anika Therapeutics has CHF 44.96M in cash and marketable securities with CHF 24.57M in debt, giving a net cash position of CHF 20.39M billion.
- Cash & Marketable Securities
- CHF 44.96M
- Total Debt
- CHF 24.57M
- Net Cash
- CHF 20.39M
- Net Cash Per Share
- CHF 1.52
- Tangible Book Value Per Share
- CHF 9.57
Margins
Gross margin is 63.40%, with operating margin of -2.11%, and net profit margin of -1.43%.
- Gross Margin
- 63.40%
- Operating Margin
- -2.11%
- Pretax Margin
- -0.81%
- Net Profit Margin
- -1.43%
- EBITDA Margin
- 4.16%
- EBIT Margin
- -0.81%
Analyst Forecast
The average price target for Anika Therapeutics is CHF 18.89, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- CHF 18.89
- Price Target Upside
- ―
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 2.43%
- EPS Growth Forecast
- 95.00%
Scores
- Smart Score
- 8
- AI Score
- ―
